Inhibitors of arginine gingipain
The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis , including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.
1. A compound according to Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Z is halogen-substituted aryloxymethyl-carbonyl;
each R 1 is independently selected from the group consisting of hydrogen, C 1-4 alkyl, and an amine protecting group;
R 2 is selected from the group consisting of hydrogen and C 1-4 alkyl;
R 3 is selected from the group consisting of C 3-8 cycloalkyl, C 3-8 alkyl, C 6-10 aryl, 5-to-12 membered heteroaryl, and 5-to-12 membered heterocyclyl,
wherein R 3 is optionally substituted with one or more R 4 substituents independently selected from the group consisting of halo, —CN, —NO 2 , —N 3 , —OH, R a , —OR b , —N(R d ) 2 , —(CH 2 ) k C(O)R c , —NR d (CH 2 ) u C(O)R c , —O(CH 2 ) u C(O)R c , —(CH 2 ) k CON(R d ) 2 , —(CH 2 ) k NR d C(O)R c , —NR d (CH 2 ) u CON(R d ) 2 , —NR d (CH 2 ) u NR d C(O)R c , —O(CH 2 ) u CON(R d ) 2 , and —O(CH 2 ) u NR d C(O)R c ;
each R a , R b , and R c is independently selected from the group consisting of C 1-4 alkyl and C 1-4 haloalkyl,
each R d is independently selected from the group consisting of hydrogen and C 1-8 alkyl,
each subscript k is independently selected from 0, 1, 2, 3, 4, 5, and 6, and
each subscript u is independently selected from 1, 2, 3, 4, 5, and 6;
provided that R 3 and the carbonyl to which it is bonded form a moiety other than prolinyl, substituted prolinyl, argininyl, substituted argininyl, phenylalaninyl, substituted phenylalaninyl, tert-butylaminocarbonyl, or tert-butyloxycarbonyl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is fluorine-substituted phenoxymethyl-carbonyl.
3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen.
4. The compound of claim 1 , having a structure according to Formula Ia:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein Z is fluorine-substituted phenoxymethyl-carbonyl.
6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is (2,3,5,6-tetrafluorophenoxymethyl)carbonyl.
8. The compound of claim 1 , having a structure according to Formula Ib:
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 3 is selected from the group consisting of C 3-8 cycloalkyl, C 6-10 aryl, 5-to-12 membered heteroaryl, and 5-to-12 membered heterocyclyl, each of which is optionally substituted with one or more R 4 substituents.
10. The compound of claim 9 , wherein R 3 is selected from the group consisting of cyclopentyl, phenyl, and azidophenyl.
11. The compound of claim 8 , which is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
12. The compound of claim 8 , which is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
13. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
14. A method of treating a disease or condition associated with P. gingivalis infection, the method comprising administering to the subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
15. The method of any one of claim 14 , wherein the disease or condition is selected from a brain disorder, periodontal disease, diabetes, a cardiovascular disease, arthritis, rheumatoid arthritis, osteoarthritis, infectious arthritis, psoriatic arthritis, elevated risk of preterm birth, pneumonia, cancer, a kidney disease, a liver disease, a retinal disorder, and glaucoma.
16. The method of claim 15 , wherein the disease or condition is a brain disorder.
17. The method of claim 16 , wherein the brain disorder is selected from Alzheimer's disease, Down's syndrome, epilepsy, autism, Parkinson's disease, essential tremor, fronto-temporal dementia, progressive supranuclear palsy, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, mild cognitive impairment, age associated memory impairment, chronic traumatic encephalopathy, stroke, cerebrovascular disease, Lewy Body disease, multiple system atrophy, schizophrenia, and depression.